Study compares standard against newer treatment in women whose breast cancer has spread

December 7, 2012

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival. This study was presented today by Peter A. Kaufman, M.D., during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

"We didn't show a statistically significant superiority of eribulin over capecitabine, which was our goal," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H. "However, eribulin demonstrated a trend favoring an overall , in comparison to capecitabine, which is a widely accepted and used standard therapy in this setting. Additionally, this is the first study demonstrating that eribulin is active earlier in the course of metastatic ," Kaufman said.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues examined whether eribulin would be effective as an earlier-line treatment in with metastatic breast cancer. They randomly assigned 1,102 patients to eribulin or capecitabine. Patients had all received prior - and taxane-based therapy and received the study drug as the first, second or third line of therapy for metastatic disease.

The median overall survival for patients treated with eribulin was 15.9 months compared with 14.5 months for patients treated with capecitabine.

"Although we did not meet our primary endpoints, this is still the first study demonstrating the activity of eribulin in earlier lines of treatment of metastatic breast cancer," Kaufman said. "Eribulin is an active therapy in this setting, and overall, it has potentially comparable activity to capecitabine, which is a widely used treatment in this patient population."

As a next step researchers are evaluating how eribulin performed among subsets of women in the study who share similar traits. Exploratory analyses of patient subsets showed that the median overall survival in women with HER2-negative breast cancer was 15.9 months with eribulin compared with 13.5 months with capecitabine. In women with triple-negative breast cancer, which is a particularly aggressive subset, the median overall survival was 14.4 months with eribulin compared with 9.4 months with .

Kaufman and colleagues are still compiling data from the quality-of-life analysis, which according to Kaufman, will help guide their next steps in further studying eribulin in this patient population.

Explore further: FDA OKs Ixempra for advanced breast cancer

Related Stories

FDA OKs Ixempra for advanced breast cancer

October 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

Drug combination shrinks breast cancer metastases in brain

December 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Marine sponge drug extends breast cancer survival: study

June 6, 2010

A new agent derived from a marine sponge can extend the survival rates of women with locally recurrent or metastatic breast cancer who already recieved extensive standard therapy, a new study unveiled Sunday found.

Recommended for you

Oxygen can impair cancer immunotherapy in mice

August 25, 2016

Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers. This mechanism involves oxygen inhibition of the anticancer ...

Stem cell propagation fuels cancer risk in different organs

August 25, 2016

The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community. Some researchers maintain that environmental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.